Genomic DNA at a programmable site (gDNA)

Genomic DNA at a programmable site refers to a specific sequence within the human genome that is targeted for precise modification by gene-editing technologies. This target serves as the fundamental blueprint for cellular function, and its alteration allows for the permanent correction of disease-causing mutations or the modulation of gene expression [Nature Biotechnology, 2023]. In therapeutic contexts, this target is accessed by systems such as CRISPR-Cas9, base editors, or zinc-finger nucleases, which are engineered to recognize a unique sequence through guide RNAs or DNA-binding domains [PubMed: 30733583]. By interacting with this target, drugs can induce site-specific changes that treat conditions like sickle cell disease, transthyretin amyloidosis, and certain hereditary cancers [NEJM, 2021]. The clinical utility of targeting genomic DNA lies in its potential for a 'one-and-done' curative effect, though it requires rigorous monitoring for off-target effects and genomic stability [Science, 2022].

Other names

Target DNA sequenceProgrammable genomic locusSite-specific genomic DNACRISPR target siteChromosomal DNA target

Therapeutic agents utilize programmable nucleases (e.g., Cas9, Cas12a) or editors to bind specific DNA sequences via Watson-Crick base pairing or protein-DNA interactions, inducing double-strand breaks, nicks, or chemical base modifications to disrupt, correct, or insert genetic information [Nature, 2022].